John O’Gorman

5.0k total citations
49 papers, 1.3k citations indexed

About

John O’Gorman is a scholar working on Physiology, Statistics and Probability and Pathology and Forensic Medicine. According to data from OpenAlex, John O’Gorman has authored 49 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Physiology, 9 papers in Statistics and Probability and 8 papers in Pathology and Forensic Medicine. Recurrent topics in John O’Gorman's work include Alzheimer's disease research and treatments (19 papers), Multiple Sclerosis Research Studies (8 papers) and Statistical Methods in Clinical Trials (6 papers). John O’Gorman is often cited by papers focused on Alzheimer's disease research and treatments (19 papers), Multiple Sclerosis Research Studies (8 papers) and Statistical Methods in Clinical Trials (6 papers). John O’Gorman collaborates with scholars based in United States, Switzerland and United Kingdom. John O’Gorman's co-authors include Brett Myors, David Shum, Katherine Dawson, Mark Novas, Samantha Budd Haeberlein, Leslie Williams, Jeff Sevigny, J L Ferrero, Alvydas Mikulskis and J. Theodore Phillips and has published in prestigious journals such as Nature Medicine, Neurology and JNCI Journal of the National Cancer Institute.

In The Last Decade

John O’Gorman

47 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John O’Gorman United States 16 418 235 188 165 164 49 1.3k
Jennifer L. Steiner United States 27 673 1.6× 256 1.1× 730 3.9× 166 1.0× 332 2.0× 86 2.4k
Veronica Ramirez United States 18 262 0.6× 122 0.5× 563 3.0× 68 0.4× 152 0.9× 34 2.0k
Yang Zheng China 28 161 0.4× 139 0.6× 296 1.6× 156 0.9× 77 0.5× 122 2.3k
Qing-Hui Zhou China 24 258 0.6× 76 0.3× 424 2.3× 133 0.8× 186 1.1× 59 1.8k
Francesca Fiore Italy 18 355 0.8× 156 0.7× 461 2.5× 64 0.4× 309 1.9× 48 1.7k
Patrice Verpillat France 24 621 1.5× 154 0.7× 415 2.2× 279 1.7× 72 0.4× 74 2.1k
Yan Han China 25 212 0.5× 110 0.5× 499 2.7× 57 0.3× 330 2.0× 94 2.0k
Musaad A. Alshammari Saudi Arabia 23 131 0.3× 122 0.5× 406 2.2× 68 0.4× 130 0.8× 55 1.2k
Ying Zhu China 22 119 0.3× 505 2.1× 226 1.2× 49 0.3× 245 1.5× 72 2.2k
Linda H. Chung Spain 23 192 0.5× 356 1.5× 578 3.1× 80 0.5× 131 0.8× 62 1.7k

Countries citing papers authored by John O’Gorman

Since Specialization
Citations

This map shows the geographic impact of John O’Gorman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John O’Gorman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John O’Gorman more than expected).

Fields of papers citing papers by John O’Gorman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John O’Gorman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John O’Gorman. The network helps show where John O’Gorman may publish in the future.

Co-authorship network of co-authors of John O’Gorman

This figure shows the co-authorship network connecting the top 25 collaborators of John O’Gorman. A scholar is included among the top collaborators of John O’Gorman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John O’Gorman. John O’Gorman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Tianle, John O’Gorman, Carmen Castrillo‐Viguera, et al.. (2024). Results from the long‐term extension of PRIME: A randomized Phase 1b trial of aducanumab. Alzheimer s & Dementia. 20(5). 3406–3415. 11 indexed citations
2.
Chen, Tianle, R. Matthew Hutchison, Philip H. Montenigro, et al.. (2024). A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 11(5). 1228–1240. 3 indexed citations
3.
Loomis, Stephanie, Carmen Castrillo‐Viguera, Kimberly Umans, et al.. (2023). Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies. Neurology. 102(3). e207919–e207919. 25 indexed citations
4.
Shulman, Melanie, Jessica Kong, John O’Gorman, et al.. (2023). TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease. Nature Aging. 3(12). 1591–1601. 47 indexed citations
5.
Jaeger, Judith, Yumeng Li, Carmen Castrillo‐Viguera, et al.. (2021). Development of a cognitive composite for measuring change in progressive supranuclear palsy. Parkinsonism & Related Disorders. 92. 94–100. 3 indexed citations
6.
Castrillo‐Viguera, Carmen, Samantha Budd Haeberlein, Philipp von Rosenstiel, et al.. (2019). Interim Analyses of Fixed-Dose and Titration Cohorts from PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Aducanumab (S9.006). Neurology. 92(15_supplement). 2 indexed citations
7.
8.
Chiao, Ping, Barry J. Bedell, Brian Avants, et al.. (2018). Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab. Journal of Nuclear Medicine. 60(1). 100–106. 39 indexed citations
9.
Ratti, Elena, Tina M. Olsson, Kumar Kandadi Muralidharan, et al.. (2018). P3‐033: RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY TO ASSESS TREATMENT OF BIIB092 IN SUBJECTS WITH EARLY ALZHEIMER'S DISEASE: TANGO PHASE 2 STUDY DESIGN. Alzheimer s & Dementia. 14(7S_Part_20). 1 indexed citations
10.
Viglietta, Vissia, John O’Gorman, Leslie Williams, et al.. (2016). Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003). Neurology. 86(16_supplement). 9 indexed citations
11.
12.
13.
Sheikh, Sarah, Ivan Nestorov, John O’Gorman, et al.. (2013). Tolerability and Pharmacokinetics of Delayed-Release Dimethyl Fumarate Administered With and Without Aspirin in Healthy Volunteers. Clinical Therapeutics. 35(10). 1582–1594.e9. 48 indexed citations
14.
Bar‐Or, Amit, Ralf Gold, Ludwig Kappos, et al.. (2013). Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study. Journal of Neurology. 260(9). 2297–2305. 59 indexed citations
15.
Hutchinson, Michael, Robert J. Fox, David H. Miller, et al.. (2013). Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study. Journal of Neurology. 260(9). 2286–2296. 74 indexed citations
16.
Miller, D. H., et al.. (2012). Effect of BG-12 on magnetic resonance imaging activity in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. UCL Discovery (University College London). 3 indexed citations
17.
Shum, David, John O’Gorman, & Brett Myors. (2006). Psychological Testing and Assessment. Griffith Research Online (Griffith University, Queensland, Australia). 107 indexed citations
18.
Gordon, Kenneth B., Akshay Vaishnaw, John O’Gorman, J. Haney, & Alan Menter. (2003). Treatment of Psoriasis With Alefacept. Archives of Dermatology. 139(12). 1563–70. 73 indexed citations
19.
Freedman, Matthew T., Jeffrey S. Martin, John O’Gorman, et al.. (2001). Digitized Mammography: a Clinical Trial of Postmenopausal Women Randomly Assigned to Receive Raloxifene, Estrogen, or Placebo. JNCI Journal of the National Cancer Institute. 93(1). 51–56. 104 indexed citations
20.
O’Gorman, John & Michael G. Akritas. (2001). Nonparametric Models and Methods for Designs with Dependent Censored Data: Part I. Biometrics. 57(1). 88–95. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer L. Steiner Breakdown of academic impact, for papers by Veronica Ramirez Breakdown of academic impact, for papers by Yang Zheng Breakdown of academic impact, for papers by Qing-Hui Zhou Breakdown of academic impact, for papers by Francesca Fiore Breakdown of academic impact, for papers by Patrice Verpillat Breakdown of academic impact, for papers by Yan Han Breakdown of academic impact, for papers by Musaad A. Alshammari Breakdown of academic impact, for papers by Ying Zhu Breakdown of academic impact, for papers by Linda H. Chung
Rankless by CCL
2026